Effect of Doxycycline on Cardiac Remodelling in STEMI Patients
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Subsequent to the loss of myocardium post-myocardial infarction (MI), the affected ventricle
undergoes some dynamic structural and functional changes known as remodeling. Cardiac
remodeling progresses into heart failure (HF). In this revolutionized percutaneous coronary
intervention (PCI) era, the incidence of post-MI HF due to cardiac remodeling remains high.
Current standard therapeutic interventions, for HF, aimed solely at correcting a low cardiac
output do not necessarily impede HF progression. Recently, doxycycline was found to have an
additional biological effect aside from their antimicrobial actions. From several
experimental studies and clinical trials, doxycycline showed MMP inhibition activities that
can prevent ventricular remodeling. This study aims to evaluate the role of doxycycline in
cardiac remodeling prevention post-MI. Our hypothesis is that a better heart function will be
observed in STEMI patients who receive a short period of doxycycline administration post-PCI.
Phase:
Phase 3
Details
Lead Sponsor:
Felix Chikita Fredy, MD
Collaborator:
National Cardiovascular Center Harapan Kita Hospital Indonesia